ArticleCNS neuroscience & therapeutics2026
CREB5 Inhibits Neuronal Ferroptosis via Transactivating ApoL6 to Regulate Lipid Droplet Metabolism After Spinal Cord Injury.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lipid droplets as redox-active organelles after spinal cord injury: lipid peroxidation, mitochondrial dysfunction, and neuroinflammation.Redox report : communications in free radical research · 2026Review
- CREB5 Inhibits Neuronal Ferroptosis via Transactivating ApoL6 to Regulate Lipid Droplet Metabolism After Spinal Cord Injury.CNS neuroscience & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAfter spinal cord injury (SCI), neuronal lipid peroxidation and excessive production of reactive oxygen species (ROS) induced by secondary injury exacerbate ferroptosis, impeding regenerative repair and functional recovery in mice. Thus, clarifying the molecular and cellular mechanisms underlying the inhibition of neuronal ferroptosis post-SCI is crucial.
methodsSingle-cell RNA sequencing (scRNA-seq) and single-cell assay for transposase-accessible chromatin sequencing (scATAC-seq) were used to analyze changes in the transcription factor CREB5 post-SCI. Combined with in vitro (primary neuron experiments) and in vivo (mouse SCI model) studies, CREB5 was knocked down/overexpressed, and ApoL6 was overexpressed. Indicators related to neuronal ferroptosis (ROS, lipid peroxidation, free fatty acids, etc.) and functional recovery in mice were detected.
resultsAfter SCI, the transcriptional activity of the transcription factor CREB5 is enhanced, and its expression level first increases and then decreases. Mechanistically, CREB5 inhibits the decomposition of neuronal lipid droplets (LDs) by enhancing the transcriptional activity of the lipolysis-related protein ApoL6, reducing the release of free fatty acids (FFA) and fatty acid oxidation (FAO), thereby decreasing ROS generation and lipid peroxidation, and ultimately inhibiting neuronal ferroptosis. In vitro experiments showed that CREB5 knockdown exacerbates neuronal death and inhibits axonal growth; in vivo experiments demonstrated that CREB5 knockdown hinders axonal growth and functional recovery in mice post-SCI, while ApoL6 overexpression partially reverses these impairments.
conclusionsCREB5 maintains the balance of neuronal lipid droplet metabolism by regulating ApoL6 and serves as a potential therapeutic target for inhibiting neuronal ferroptosis after SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.